Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987511 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL8258339 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL28338117 | 0.88 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL28338118 | 0.88 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL21822929 | 0.88 | STAT3 (0.43) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL23387619 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL20501797 | 0.86 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL23387620 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1CYP2C9L3MBTL1 | |
| SCHEMBL7032005 | 0.85 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9ENPP3 | |
| SCHEMBL26655167 | 0.85 | CYP2D6 (0.45) | ALDH1A1KMT2AMEN1CYP2C9ENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| EP-3969458-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2021-06-24 | — | — | US | disclosed |
| WO-2020232470-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| CN-110809574-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ALDH1A1 1615/4885KMT2A 3153/4885MEN1 4390/4885 |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | ALDH1A1 2478/4885KMT2A 616/4885MEN1 1421/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ALDH1A1 1584/4885KMT2A 3232/4885MEN1 3150/4885 |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | ALDH1A1 187/4885KMT2A 2176/4885MEN1 2360/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | ALDH1A1 1567/4885KMT2A 4296/4885MEN1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.